Hepatocellular Adenomas: The Review of Current Data
https://doi.org/10.37174/2587-7593-2019-2-3-63-72
Abstract
Hepatocellular adenomas are rare benign liver tumors with extremely variable pathology, molecular and etiology features.
Their molecular and genetic correlations help to stratify patients for further follow-up and help to make clinical decisions because of natural behavior of different HCA’s subtypes.
In the review we try to compile the last available information about hepatocellular adenomas.
About the Authors
B. M. Medvedeva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
D. M. Khaitsman
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
A. B. Lukianchenko
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
References
1. Katabathina V.S., Menias C.O., Shanbhogue A.K., Jagirdar J. et al. Genetics and imaging of hepatocellular adenomas: 2011 update // Radiographics. 2011. Vol. 31. № 6. P. 1529-1543.
2. Baum J.K., Bookstein J.J., Holtz F., Klein E.W. et al. Possible association between benign hepatomas and oral contraceptives // Lancet. 1973. Vol. 302. P. 926-929.
3. Calderaro J., Labrune P., Morcrette G. et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type // J. Hepatol. 2013. Vol. 58. P 350-357.
4. Bioulac-Sage P. et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience // Hepatology. 2009. Vol. 50. № 2. P 481-489.
5. Colombo M., Zucman-Rossi J., Forner A. et al. Клинические рекомендации EASL по ведению пациентов с доброкачественными опухолями печени // J. Hepatol. 2016. Vol. 65. P. 386-398.
6. Nault J.C., Couchy G., Balabaud C. et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation // Gastroenterology. 2017. Vol. 152. № 4. P 880-894.
7. Shanbhogue A.K., Prasad S.R., Takahashi N. et al. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management // Radiology. 2011. Vol. 258. P 673-693.
8. Dokmak S., Paradis V., Vilgrain V. et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas // Gastroenterology. 2009. Vol. 137. P. 1698-1705.
9. Pelletier L., Rebouissou S., Paris A. et al. Loss of hepatocyte nuclear factor 1 alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorogenesis // Hepatology. 2010. Vol. 51. P 557-566.
10. Rebouissou S., Imbeaud S., Balabaud C et al. HNF1 alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation // J. Biol. Chem. 2007. Vol. 282. P. 4437-14446.
11. Ronot M., Bahrami S., Calderaro J. et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification // Hepatology. 2011. Vol. 53. P. 1182-1191.
12. Rebouissou S., Franconi A., Calderaro J. et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different 6-catenin activity associated with liver tumor progression // Hepatology 2016. [Epub ahead of print].
13. Bioulac-Sage P, Rebouissou S., Thomas C. et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry // Hepatology. 2007. Vol. 46. P. 740-748.
14. Bioulac-Sage P., Le Bail P., Castain C. et al. Different types of glutamine synthetase immunostaining in hepatocellular adenoma // Mod Pathol. 2016. Vol. 24. №S2. P. 415-423.
15. Pilati C., Letouze E., Nault J.C. et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation // Cancer Cell. 2014. Vol. 25. P 428-441.
16. Sempoux C., Bisig B., Couchy G. et al. Malignant transformation of a b-catenin inflammatory adenoma due to a S45 6-catenin activating mutation present 12 years before // Hum. Pathol. 2017. Vol. 62. P. 122-125.
17. Nault JC., Paradis V., Cherqui D. et al. Molecular classification of hepatocellular adenoma in clinical practice // J. Hepatol. 2017. Vol. 67. P 1074-1083.
18. Laumonier H., Bioulac-Sage P., Laurent C. et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification // Hepatology. 2008. Vol. 48. P. 808-818.
19. Ronot M., Bahrami S., Calderaro J. et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification // Hepatology. 2011. Vol. 53. P. 1182-1191.
20. van Aalten S.M., Thomeer M.G., Terkivatan T. et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification // Radiology. 2011. Vol. 261. P. 172-181.
21. Chang C.Y., Hernandez-Prera J.C., Roayaie S. et al. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature // Int. J. Hepatol. 2013. Vol. 60. P. 48-60.
22. Taimr P., Broker M.E.E., Dwarkasing R.S. et al. A model-based prediction of the probability of hepatocellular adenoma and focal nodular hyperplasia based on characteristics on contrast-enhanced ultrasound // Ultrasound Med Biol. 2017. Vol. 43. № 10. P. 2144-2150.
23. Yoneda N., Matsui O., Kitao A. et al. Benign hepatocellular nodules: hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background // Radiographics. 2016. Vol. 36. № 7. P. 2010-2027.
24. Sciarra A., Schmidt S., Pellegrinelli A. et al. OATPB1/ B3 and MRP3 expression in hepatocellular adenoma predicts Gd- EOB-DTPA uptake and correlates with risk of malignancy // Liver Int. 2019. Vol. 39. № 1. P 158-167.
25. Srinivasa S., Lee W.G., Aldameh A., Koea J.B. Spontaneous hepatic haemorrhage: a review of pathogenesis., aetiology and treatment // HPB (Oxford). 2015. Vol. 17. № 10. P 872-880.
26. van Aalten S.M., de Man R.A., IJzermans J.N. et al. Systematic review of haemorrhage and rupture of hepatocellular adenomas // Brit. J. Surg. 2012. Vol. 99. № 7. P 911-916.
27. Bieze M., Phoa S.S., Verheij J. et al. Risk factors for bleeding in hepatocellular adenoma // Brit. J. Surg. 2014. Vol. 101. № 7. P 847-855.
28. Deneve J.L., Pawlik T.M., Cunningham S. et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy // Ann. Surg. Oncol. 2009. Vol. 16. № 3. P. 640-648.
29. Klompenhouwer A.J., de Man R.A., Thomeer M.G. et al. Management and outcome of hepatocellular adenoma with massive bleeding at presentation // World J. Gastroenterol. 2017. Vol. 23. № 25. P. 4579-4586.
30. Stoot J.H., Coelen R.J., De Jong M.C. et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases // HPB (Oxford). 2010. Vol. 12. № 8. P. 509-522.
31. Farges O., Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature // Dig. Surg. 2010. Vol. 27. № 1. P. 32-38.
32. Bossen L., Gronbaek H., Lykke Eriksen P. et al. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: a nationwide population- based study //Liver Int. 2017. Vol. 37. № 7. P. 1042-1046.
33. Zucman-Rossi J., Jeannot E., Nhieu JT. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC // Hepatology. 2006. Vol. 43. № 3. P. 515-524.
34. Newhook T.E., LaPar D.J., Lindberg J.M. et al. Morbidity and mortality of hepatectomy for benign liver tumors // Amer. J. Surg. 2016. Vol. 211. № 1. P 102-108.
35. Hoffmann K., Unsinn M., Hinz U. et al. Outcome after a liver resection of benign lesions // HPB (Oxford). 2015. Vol. 17. № 11. P. 994-1000.
36. Liau S.S., Qureshi M.S., Praseedom R. et al. Molecular pathogenesis of hepatic adenomas and its implications for surgical management // J. Gastrointest. Surg. 2013. Vol. 17. № 10. P 1869-1982.
37. Landi F., De’ Angelis N., Scatton O. et al. Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: a multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group // Surg. Endosc. 2017. Vol. 31. № 10. P. 4136-4144.
38. Agrawal S., Agarwal S., Arnason T. et al. Management of hepatocellular adenoma: recent advances // Clin. Gastroenterol. Hepatol. 2015. Vol. 13. № 7. P 1221-1230.
39. van Rosmalen B.V., Coelen R.J.S., Bieze M. et al. Systematic review of transarterial embolization for hepatocellular adenomas // Brit. J. Surg. 2017. Vol. 104. № 7. P. 823-835.
40. Zhao C., Pei SL., Cucchetti A. et al. Systematic review: benefits and harms of transarterial embolisation for treating hepatocellular adenoma // Aliment Pharmacol. Ther. 2017.
41. Mironov O., Jaberi A., Beecroft R. et al. Retrospective single-arm cohort study of patients with hepatocellular adenomas treated with percutaneous thermal ablation // Cardiovasc. Interv. Radiol. 2018. Vol. 41. № 6. P. 935941.
42. Smolock A.R., Cristescu M.M., Potretzke T.A. et al. Microwave ablation for the treatment of hepatic adenomas // J. Vasc. Interv. Radiol. 2016. Vol. 27. № 2. P. 244-249.
43. Sundar Alagusundaramoorthy S., Vilchez V., Zanni A. et al. Role of transplantation in the treatment of benign solid tumors of the liver: a review of the United Network of Organ Sharing data set // JAMA Surg. 2015. Vol. 150. № 4. P. 337-342.
44. Chiche L., David A., Adam R. et al. Liver transplantation for adenomatosis: European experience // Liver Transpl. 2016. Vol. 22. № 4. P 516-526.
45. Thapar M., Grapp O., Fisher C. Management of hepatic adenomatosis // Curr. Gastroenterol. Rep. 2015. Vol. 17. № 3. P. 12-17.
46. Лукьянченко А.Б., Медведева Б.М. Современные возможности лучевой диагностики гепатоцеллю-лярных аденом (обзор литературы и собственные наблюдения) // Медицинская визуализация. 2013. T. 1. C. 33-43.
47. van Aalten S.M., Terkivatan T., de Man R.A. et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences // Dig. Surg. 2010. Vol. 27. № 1. P. 61-67.
48. van Aalten S.M., Witjes C.D., de Man R.A. et al. Can a decisionmaking model be justified in the management of hepatocellular adenoma? // Liver Int. 2012. Vol. 32. № 1. P 28-37.
49. Sinclair M., Schelleman A., Sandhu D. et al. Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy // Hepatology. 2017. Vol. 66. № 3. P. 989-991.
50. Dokmak S., Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? // Liver Int. 2015. Vol. 35. № 10. P. 2228-2232.
51. Khaoudy I., Rebibo L., Regimbeau J.M. Is bariatric surgery a potential new treatment for large inflammatory hepatocellular adenomas in obese patients? // Surg. Obes. Relat. Dis. 2018. Vol. 14. № 4. P. 535-538.
Review
For citations:
Medvedeva B.M., Khaitsman D.M., Lukianchenko A.B. Hepatocellular Adenomas: The Review of Current Data. Journal of oncology: diagnostic radiology and radiotherapy. 2019;2(3):63-72. (In Russ.) https://doi.org/10.37174/2587-7593-2019-2-3-63-72
Views:
1243
Email this article 